INNOVATIONS
-
The AAV gene therapy, under co-development of Reyon Pharmaceutical and Neuracle Genetics, has received approval for phase 1/2a clinical trials in Canada
-Reyon Pharmaceutical secures exclusive production and supply rights for raw materials and finished products worldwide through the 2020 joint development agreement for gene therapy (NG101) for wet age-related macular degeneration (wAMD). -Initiation of clinical trials in 3Q23 Expand clinical trials to the United States in the future Reyon Pharmaceutical (Representative Directors: Jung SoonOck, Yoo Yonghwan) announced on the 2nd that the company had received approval from the Ministry of Health ...
2023.05.02
-
Reyon Pharmaceutical signed a joint development agreement with Therabest for NK cell therapy
- Joint development of TB-100, an NK cell therapy against solid cancers - Profit sharing and exclusive supply of pDNA for cell therapy production Reyon Pharmaceutical expands its biopharmaceutical business through the joint development of NK cell therapy. (Ki Pyeong-seok (left), CEO of Therabest, Yoo Yonghwan (right), Representative Director of Reyon Pharmaceutical) Reyon Pharmaceutical (Representative Directors: Jung SoonOck, Yoo Yonghwan) announced on the 11th that the company had signed a jo...
2023.04.11
-
Reyon Pharmaceutical signed an MOU with Connext for comprehensive business cooperation in the CDMO business
Reyon Pharmaceutical will take its CDMO business to the next level through business cooperation with Connext. (Lee Woo-jong (left), CEO of Connext, Yoo Yonghwan (right), Representative Director of Reyon Pharmaceutical) Reyon Pharmaceutical (Representative Directors: Jung SoonOck, Yoo Yonghwan) announced on the 14th that the company had signed a comprehensive MOU with Connext (CEO Lee Woo-jong) for the biopharmaceutical CDMO (contract development and manufacturing) business. Through this MOU, th...
2022.12.14
-
Reyon Pharmaceutical signed an MOU with Protium Science for comprehensive business cooperation for CDMO business
Reyon Pharmaceutical expands its CDMO business through business cooperation with Protium Science. (Kim Hoon-taek (left), CEO of Protium Science, Yoo Yonghwan (right), Representative Director of Reyon Pharmaceutical) Reyon Pharmaceutical (Representative Directors: Jung SoonOck, Yoo Yonghwan) announced on the 6th that the company had signed a comprehensive MOU with Protium Science (CEO Kim Hoon-taek) for the biopharmaceutical CDMO (contract development and manufacturing) business. Through this MO...
2022.12.06
